Company / Cost of Revenue
TEVA PHARMACEUTICAL INDUSTRIES LTD Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$8.3B
FY2025
5-year range
$8.0B / $8.5B
FY2021-FY2025
Trend
-1.9%
vs FY2024
Sector context
#9 of 85
Health Care
What the data says
TEVA PHARMACEUTICAL INDUSTRIES LTD's cost of revenue of $8.3B is higher than 89% of companies in the Health Care sector (FY2025). Cost of Revenue has fluctuated over the past 10 years, ranging from $8.0B in FY2022 to $11.2B in FY2017.
Based on SEC 10-K filings.
$8.3B in FY2025 with a 5-year CAGR of -1.4%. Top quartile in the Health Care sector.
Remained stable around $8.3B over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +1.5%
- 5-Year CAGR
- -1.4%
- 10-Year CAGR
- -
Sector benchmark
+319.6% above sector average
Key checks
Key Insights
- 5-year CAGR of -1.4%, indicating a declining trend.
- In FY2025, cost of revenue decreased 1.9% year-over-year.
- Ranks #9 out of 85 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.3B | -1.9% |
| FY2024 | $8.5B | +3.4% |
| FY2023 | $8.2B | +3.1% |
| FY2022 | $8.0B | -4.0% |
| FY2021 | $8.3B | -7.3% |
| FY2020 | $8.9B | -4.5% |
| FY2019 | $9.4B | -6.3% |
| FY2018 | $10.0B | -11.2% |
| FY2017 | $11.2B | +9.6% |
| FY2016 | $10.3B | +23.6% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026